Literature DB >> 12681967

Immunophenotypic analysis of myelodysplastic syndromes.

M Consuelo Del Cañizo1, M Eugenia Fernández, Antonio López, Belén Vidriales, Eva Villarón, José L Arroyo, Francisco Ortuño, Alberto Orfao, Jesus F San Miguel.   

Abstract

BACKGROUND AND OBJECTIVES: In contrast with hematologic malignancies in which the value of immunophenotypic studies is well established, information on the immunophenotypic characteristics of myelodysplastic syndromes (MDS) is scanty. The main goal of the present study was to explore the immunophenotypic differences between patients with MDS and normal individuals, including changes in distribution of cell lineages as well as phenotypic aberrations and blockades in cell maturation pathways. DESIGN AND METHODS: In MDS the proportion of bone marrow CD34+ cells was higher than in normal patients but the most immature progenitors (CD34+CD38-) were less represented. By contrast the proportion of myelomonocytic CD34+ cells was greater than in normal individuals, translating into an increased myeloid/non-myeloid CD34+ hematopoietic progenitor cell ratio.
RESULTS: This suggests that in MDS, the majority of CD34+ cells are already committed to the myeloid lineage. Upon analyzing the granulo-monocytic differentiation pathway, MDS patients showed an increased proportion of monocytic cells with a decreased percentage of cells of neutrophil lineage, leading to a lower neutrophil/monocytic cell ratio. Maturational arrests in the monocytic but not in the neutrophil differentiation pathway were observed. In refractory anemia with excess blasts in transformation (RAEB-t) such blockades mainly occurred during the earliest stages of differentiation but in the other MDS subtypes they occurred in later stages. INTERPRETATION AND
CONCLUSIONS: Phenotypic aberrations occurred in 90% of patients and a high proportion of cases showed >=2 aberrations. In summary, our results show that, in addition to an abnormal distribution of the bone marrow cell compartment, MDS patients frequently show aberrant phenotypes and maturational arrests. Some of these features may help in cases in which the diagnosis of MDS is questionable.

Entities:  

Mesh:

Year:  2003        PMID: 12681967

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  4 in total

1.  Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes.

Authors:  Alex F Sandes; Mihoko Yamamoto; Sergio Matarraz; Maria de Lourdes L F Chauffaille; Sandra Quijano; Antonio López; Tsutomu Oguro; Eliza Y S Kimura; Alberto Orfao
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

Authors:  Peter L Greenberg; Zhuoxin Sun; Kenneth B Miller; John M Bennett; Martin S Tallman; Gordon Dewald; Elisabeth Paietta; Richard van der Jagt; Jessie Houston; Mary L Thomas; David Cella; Jacob M Rowe
Journal:  Blood       Date:  2009-06-29       Impact factor: 22.113

3.  Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes.

Authors:  Nicolas Goardon; Emmanouil Nikolousis; Alexander Sternberg; Wai-Kit Chu; Charles Craddock; Peter Richardson; Richard Benson; Mark Drayson; Graham Standen; Paresh Vyas; Sylvie Freeman
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

4.  Bone marrow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone marrow microenvironment.

Authors:  Soraya Carrancio; Belen Blanco; Carlos Romo; Sandra Muntion; Natalia Lopez-Holgado; Juan F Blanco; Jesus G Briñon; Jesus F San Miguel; Fermin M Sanchez-Guijo; M Consuelo del Cañizo
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.